India's Wockhardt, facing a raft of regulatory issues from the U.S. and Europe, is beefing up its quality oversight with a new leader for its regulatory and compliance division.
The Ohm Laboratories plant in New Jersey is currently Ranbaxy's only facility able to turn out product for the U.S. market. Now the FDA has raised questions about manufacturing practices at the active pharmaceutical plant that supplies about 70% of the raw ingredients for U.S. production, Ranbaxy's facility in Toansa.
A probe by Chinese authorities into alleged corruption in its pharma industry initially focused on drug manufacturers, and Western companies at that. But with the announcement that the former vice president of China's largest drug distributor has been detained, it has moved down the supply chain and firmly into its domestic industry. It also involves a company in a piece of the industry that is key to foreign drugmakers and one that has been tricky for them to navigate.
Back in September, EU leaders slammed China for targeting foreign drugmakers in its crackdown on pharma corruption. Chinese officials denied passing over domestic violations, and now, it seems, they're investigating a local company with full force: Shanghai authorities have detained a former vice president of local company Sinopharm, the country's biggest drug distributer, as part of a corruption probe.
Italian cardiac device giant Sorin will ally with a Chinese competitor to help it grab a stake in China's surging healthcare market.
Indian med tech startup Forus Health raised $8 million in Series B cash to expand the use of its 3nethra device, a low-cost eye scanner designed to help diagnose ophthalmic ailments in under-served regions.
Quest Diagnostics has made a great deal of headway in India over the past 6 years, as the oft-downgraded giant is looking to diversify its revenue sources in the face of reimbursement challenges at home.
After years of allowing loosely regulated clinical trials that often put patients at risk, the Indian government has taken a 180-degree turn, now further strengthening its rules by mandating that ethics committees must be registered and accredited before a study can begin.
Chinese authorities say they will blacklist drugmakers caught bribing doctors and other health authorities--and those companies will be barred from selling their products, at first regionally, and then nationally for a second offense.
Foreign drugmakers have had their fair share of struggles in China this year as the country looked to cut down on healthcare spending and root out bribery. But neither of those factors caused a Tuesday holdup of a Pfizer drug. Instead, the company is blaming a paperwork problem for an import suspension on antifungal drug Diflucan.